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VaccineThe varicella-zoster virus (VZV) Oka vaccine strain (vOka) differs from the parental strain (pOka) at several
amino acid positions, but the mutations responsible for the attenuation of vOka have not been clearly
deﬁned. The ORF0 of vOka carries some of the mutations. Although we found that the ORF0 of both strains
was incorporated into virus particles, the C-terminal region of vOka ORF0 was presented on the virion
surface and was N-glycosylated, suggesting that the mutation in vOka ORF0 changes it into a novel envelope
glycoprotein. In a mutant virus in which pOka ORF0 was replaced by vOka ORF0, the molecular weight of
ORF0 was altered, but the plaque size was not. In addition, a pOka recombinant virus lacking the
hydrophobic domain of ORF0 grew equally well as the wild-type virus, indicating that the mutation in ORF0
is not by itself sufﬁcient for the attenuation of the vOka virus.nd Vaccinology, Division of
Innovation, 7-6-8, Saito-Asagi,
.
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Varicella-zoster virus (VZV) is a member of the human alphaher-
pesvirus subfamily and causes chickenpox (varicella) and shingles
(zoster) (Cohen et al., 2007). Varicella is highly infectious. In children,
it is associated with fever and generalized pruritic vesicular rash. The
virus establishes latency in cells of the dorsal root ganglia during the
primary infection. Herpes zoster is caused by the reactivation of VZV
and is usually observed later in life.
To control VZV infection, a live attenuated vaccine (vOka) was
developed from the Oka parental strain (pOka) (Takahashi et al., 1974).
The attenuated vOka was obtained by multiple passages of pOka
through human and guinea pig cells. The resulting attenuated strain
became the ﬁrst herpesvirus vaccine licensed for use in humans.
Vaccination with vOka is efﬁcient and causes few adverse events.
Consequently, it is the only strain to be used worldwide (Arvin, 2001;
Chaves et al., 2008). Although vOka's infectivity is attenuated in the skin
zenograft SCID-hu mouse model (Moffat et al., 1998), it retains the
capacity to downregulate the expression of major histocompatibility
complex class I (Abendroth et al., 2001). The delay in the production of
infectious vOka at the site of subcutaneous inoculation allows enough
time for the induction of adaptive immunity. Despite its widespread useand effectiveness as a vaccine, however, the molecular mechanisms of
vOka's attenuation are not well understood,.
A comparison of the pOka and vOka genomic sequences byGomi et al.
(2002) showed 42 mutated sites in vOka, with 20 amino acid
substitutions in open reading frames (ORFs). In addition, Kemble et al.
(2000) showed another amino acid substitution in ORF0. Therefore, a
total of 21 amino acid substitutions are found in the ORFs of vOka. The
sequence polymorphisms presented in Gomi et al. (2000) show only 15
of these 21 substitutions because vOka consists of a mixture of closely
related viruses. The remaining 6 amino acid substitutions are located in
ORF0, ORF6, and ORF62 and may contribute to the vOka attenuation.
The amino acid substitution in ORF0 is particularly interesting. ORF0
is encoded at the start site on the left side of the unique long (UL) region
of the VZV genome. It is a positional and sequence homolog of herpes
simplex virus type 1 (HSV-1) and type 2 (HSV-2) UL56. Neither ORF0
nor UL56 has an N-terminal signal sequence, and both possess a
transmembrane domain (TMD) at the C-terminus (Koshizuka et al.,
2002). These are features of tail-anchored (TA) proteins (Borgese et al.,
2003;HighandAbell, 2004; Kutay et al., 1993;Wattenberg and Lithgow,
2001). The ORF0 protein of vOka possesses an extended C-terminal
sequence because of a point mutation in its stop codon (Kemble et al.,
2000). Finally, an ORF0-null VZV mutant, generated by using the
bacterial artiﬁcial chromosome (BAC) system, shows severely retarded
growth both in vitro and in vivo (Zhang et al., 2007).
In the present study, we investigated the role of ORF0 in VZV
attenuation by preparing anti-ORF0mono-speciﬁc antibodies in rabbits
and characterizing the ORF0 protein. We found that ORF0 is incorpo-
rated into virus particles and that the extended C-terminal domain of
Table 1
The properties of ORF0 variants.
Amino
acids
Pattern of Western
blotting
N-glycosylation Intracellular
localization
pOka ORF0 129 17 kDa No Plasma membrane
vOka ORF0
spliced
155 19–30 kDa
Smeared
Yes Plasma membrane
vOka ORF0
unspliced
221 20 kDa No Cytoplasm
281T. Koshizuka et al. / Virology 405 (2010) 280–288vOka ORF0, but not the wild-type ORF0 of pOka, is N-glycosylated and
presented on the surface of the virion.
Results
Construction of the ORF0 gene
The ORF0 protein is encoded by the nucleotide (nt) sequence from
position 172 to 558 of the pOka genome. The stop codon of pOka ORF0 is
atnucleotide(nt)position559of thepOkagenome. The thymineatnt559
of thepOkagenome is replacedby a cytosine in the vOkagenome (Fig. 1A,
arrowhead), and the resulting protein indicates that the ORF0 gene lies
between nt positions 172 and 834 of the vOka genome (Kemble et al.,
2000). TheORF0geneencodes a splicedmRNA inaddition to anunspliced
one(Fig. 1). Becausebothof thevOkaORF0geneproducts arepredicted to
be translated, both variants were cloned into plasmids and sequenced.
The stop codon of the spliced vOka ORF0 was at nt position 767, and
the splice junction was at nt positions 583 to 714. The stop codon of the
unspliced ORF0 was at nt position 835. Two single nucleotide
polymorphisms have been reported at positions 702 and 762 (Fig. 1A,Fig. 1. Schematic representation of the VZV genome and ORF0 gene. (A) The VZV genome
is shownwith its unique long(UL) andunique short (US) regions. The start of theUL region
is shown. The ORF0 and ORF1 mRNAs are illustrated, and their directions are indicated by
arrows. Open arrowheads indicate the sites of single nucleotide polymorphisms in the
vOka genome. The start and stop codons of ORF0 are indicated. The numbers indicate the
nucleotide positions in the VZV genome. (B) The predicted ORFs of ORF0 are indicated by
boxes. Grayboxes indicate theputative TMD. TheputativeN-glycosylation sites atN65 and
N126 are denoted by “N.” The vertical line indicates the amino acid polymorphism alanine
orvalineat aminoacidposition154of thevOkaORF0. Thenumbers indicate theaminoacid
positions. The amino acid length of the ORF encoded by each mRNA is given at right.
(C) Kyte and Doolittle hydrophobicity plot of pOka ORF0. The window size used was 21
amino acids.open arrowheads) of the vOka genome. These are located within the
ORF1 gene (Gomi et al., 2002) (Fig. 1A). In the spliced vOka ORF0, the
polymorphism at 702 was spliced out, and the one at nt 762 caused a
substitution of valine for alanine, at amino acid position 154 (Fig. 1B,
vertical line). In the unspliced vOka ORF0, the nt mutations were silent
and therefore did not affect the amino acid sequence. Therefore, the
ORF0 protein of pOka contains 129 amino acids (aa); the spliced variant
of vOka ORF0 contains 155 aa, and the unspliced one contains 221 aa
(Fig. 1B). Themolecularweight of eachORF0 protein predicted from the
amino acid sequencewas 14 kDa in pOka, 17 kDa for the spliced form in
vOka, and 23 kDa for the unspliced form in vOka (Table 1).
Predicted C-terminal transmembrane domain and classiﬁcation of ORF0
The ORF0 protein contains a C-terminal hydrophobic domain from
amino acids 100 to 120 (Figs. 1B and C). We generated a Kyte and
Doolittle (1982) hydrophobicity plot and applied the SOSIU algorithm
(Hirokawa et al., 1998). The results indicated that ORF0 has a single
TMD at its C-terminus but no N-terminal signal sequence (Fig. 1C).
Since these are the deﬁning characteristics of TA proteins (Koshizuka
et al., 2002), the HSV-2 homolog of VZV ORF0 is a TA protein.
Expression of ORF0 proteins
To detect the ORF0 proteins, we generated rabbit antibodies
against the N-terminal region of ORF0. On immunoblots, one of theFig. 2. Production of the ORF0 protein in VZV-infected cells. (A) MRC5 cells were mock
infected (m) or infected with strain pOka or vOka by cell-to-cell spread and harvested
at various times post-infection. Samples were separated by SDS–PAGE and analyzed by
western blotting with an anti-gB (top) or anti-ORF0 (bottom) antibody. Molecular mass
markers at left give values in kilodaltons (kDa). (B) Intracellular localization of ORF0 in
VZV-infected cells. MRC5 or MeWo cells were mock infected or infected with strain
pOka or vOka cell-free virus at moi 0.01. pOka- and vOka-infected cells were ﬁxed at
48 hpi and 72 hpi, respectively, and subjected to confocal microscopic analysis. Scale
bar: 15 μm.
Fig 2 (continued).
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with either pOka or vOka (Fig. 2A). ORF0 was detected as a 17-kDa
polypeptide in pOka-infected cells at 24 hpi and thereafter. In vOka-
infected cells, the ORF0 was detected as a smeared band of 19- to 30-
kDa polypeptides, beginning at 48 hpi.Indirect immunoﬂuorescence was used to determine the intracel-
lular localization of ORF0 in VZV-infected cells (Fig. 2B). pOka- and
vOka-infected cells were ﬁxed, respectively, at 48 and 72 hpi. In MRC-5
cells infectedwitheithervirus, theORF0 immunoreactivity accumulated
at the perinuclear region of the cytoplasm and at the plasmamembrane.
Fig. 3. Expression of ORF0 splice variants. (A) Intracellular localization of splice variants of ORF0. MeWo cells were transfected with the expression plasmid encoding pOka-ORF0
(pORF0), spliced vOka ORF0 with alanine at 154 (vORF0A), spliced vOka ORF0 with valine at 154 (vORF0V), or splicing-incompetent vOka ORF0 (vORF0N). Cells were stained with
the anti-ORF0 antibody. (B) 293T cells were transfected with the expression plasmid encoding pOka-ORF0 (P: lane 2), spliced vOka ORF0 with alanine at 154 (vA: lane 3), spliced
vOka ORF0with valine at 154 (vV: lane 4), splicing-incompetent vOka ORF0 (vN: lane 5), or control (C: lane 1), and the cell lysates were separated by 13% SDS–PAGE and analyzed by
western blotting with an anti-ORF0 antibody. Molecular mass markers are indicated at the left in kDa.
Fig. 4. N-linked glycosylation of vOka ORF0. (A) An expression plasmid encoding pOka-
ORF0 (pORF0: lanes 4–6), spliced vOka ORF0 with alanine at 154 (vORF0A: lanes 7–9),
spliced vOka ORF0 with valine at 154 (vORF0V: lanes 10–12) splicing-incompetent vOka
ORF0 (vORF0N: lanes 13–15), or the control vector (vector: lanes 1–3)was transfected into
293T cells. The cell lysateswere treatedwith PNGase-F (F: lanes 2, 5, 8, 11, 14), Endo-H (H:
lanes 3, 6, 9, 12, 15), or without endoglycosidase (−: lanes 1, 4, 7, 10, 13). Samples were
separated by SDS–13% PAGE and analyzed by western blotting. (B) VZV-infected cell
lysateswere analyzedwith endoglycosidase. Lysates ofmock-infected (lanes 1–3) or pOka
(lanes 4–6)- or vOka (lanes 7–9)-infected cells were treated with PNGase-F (F: lanes 2, 5,
8), Endo-H (H: lanes 3, 6, 9), or without endoglycosidase (−: lanes 1, 4, 7). Samples were
separated by SDS–PAGE and analyzed by western blotting.
283T. Koshizuka et al. / Virology 405 (2010) 280–288InMeWo cells infectedwith either pOka or vOka, the anti-ORF0 staining
was marked at the plasma membrane and visible at the perinuclear
region. In both cell lines, ORF0 partially colocalized with gB, a viral
envelope glycoprotein (Fig. 2B).
Expression of vOka ORF0 splice variants
To determine whether the differing C-termini of the vOka ORF0
variants led to a difference in their intracellular localizations, we
constructed the corresponding ORF0 expression plasmids and exam-
ined their expression in transfected cells (Fig. 3). The anti-ORF0 staining
for pOka ORF0 (Fig. 3A, pORF0)was found predominantly at the plasma
membrane aswas the splice variant of vOka ORF0with the alanine at aa
154 (Fig. 3A, vORF0A) and vORF0V, with a valine at aa 154 (Fig. 3A,
vORF0V). The vOka ORF0 unspliced variant (vORF0N)wasmislocalized,
in that it was distributed throughout the cytoplasm (Fig. 3A).
Toevaluate the contributionof theORF0C-terminus to eachvariant's
band pattern on immunoblots, we used the lysates of transfected cells.
pORF0 was detected as a 17-kDa polypeptide in these lysates (Fig. 3B,
lane 2), as in the lysates of pOka-infected cells. Similarly, like theORF0of
vOka-infectedcells, vORF0A(Fig. 3B, lane3) andvORF0V (Fig. 3B, lane4)
appeared as smearedbands. In contrast, vORF0Nwasdetected as a sharp
band of 20 kDa (Fig. 3B, lane 4). Therefore, the C-termini of the splice
variants of vOka ORF0 caused the smeared band pattern.
N-linked glycosylation of vOka ORF0
To determine the speciﬁc cause of the smearing on the immuno-
blots, cells transfected with ORF0 plasmids or infected with VZV were
Fig. 5. The identiﬁcation of ORF0 protein in VZV virus particles. (A) The virus particles of VZV were puriﬁed on a CsCl density gradient. The puriﬁed pOka (p) or vOka (v) virus
particles were analyzed by western blotting with anti-gB, anti-ORF0, anti-ORF49, anti-ORF16, and anti-EEA1 antibodies. PCR was done as described in Materials and methods.
284 T. Koshizuka et al. / Virology 405 (2010) 280–288treated with endoglycosidases (Fig. 4). Although PNGase-F had no
affect on the pORF0 band pattern (Fig. 4A, lane 5), both vORF0A
(Fig. 4A, lane 8) and vORF0V (Fig. 4A, lane 11) migrated faster after
the treatment. Endo-H did not change the band patterns of vORF0A or
vORF0V (Fig. 4A, lane 9). However, the vORF0N band was not altered
by either PNGase-F or Endo-H treatment (Fig. 4A, lanes 13–15).
Likewise, in the lysates of VZV-infected cells, the bands for vOka ORF0
were smaller after PNGase-F treatment but not after Endo-H
treatment (Fig. 4B, lanes 8 and 9). Thus, the vOka ORF0 protein
translated from either splice variant is a glycoprotein modiﬁed with
complex N-linked oligosaccharides.Fig. 6. Orientation of ORF0 in virus particles. (A) Puriﬁed virus particles were treatedwith
ProK with or without detergent. The samples were separated by SDS–PAGE and analyzed
by western blotting. Molecular mass markers are indicated at left. (B) Schematic
representation of the membrane orientation of ORF0 proteins. The N-terminus of ORF0
faces the tegument of virus particles. The C-terminus of vOka ORF0 is presented on the
surface of virus particles with N-linked glycosylation.ORF0 is incorporated into virus particles
To determine whether the ORF0 protein is a component of virus
particles, pOka, and vOka virus particles were puriﬁed on a CsCl
gradient and analyzed by western blotting (Fig. 5). The peak fraction
that contained virus particles was determined by PCR (Fig. 5). As
shown in Fig. 5, ORF0 proteins were detected in the peak fraction of
both pOka and vOka. An envelope protein, gB, and a tegument protein,
ORF49, which is the homologue of HSV UL11, were used as virus
particle markers. In support of this ﬁnding, neither a non-structural
viral protein, ORF16, which is the homologue of HSV UL42, nor a
cellular protein, EEA1, was detected in the peak fraction. These results
indicate that virus particles were puriﬁed successfully and that the
ORF0 protein is a component of both pOka and vOka virus particles.
To determine the membrane orientation of the ORF0 proteins,
puriﬁed VZV virus particles were treated with Proteinase K (ProK) in
the presence or absence of detergent and then analyzed by western
blotting (Fig. 6A). Proteins presented on the outside of virus particles,
such the envelope glycoprotein gB, were sensitive to ProK both in the
presence and absence of detergent (Fig. 6A, lanes 3, 4, 7, 8). The pOka
ORF0 was sensitive to ProK only in the presence of detergent (Fig. 6A,
lanes 3, 4), indicating that the N-terminus of pOka ORF0 was
protected from ProK by the envelope and faced the tegument. The
smeared bands of vOka ORF0 were sensitive to ProK in the absence of
detergent (Fig. 6A, lane 7), and the vOka ORF0 band was shifted down
to the molecular weight of pOka ORF0. The vOka ORF0 was also
sensitive to ProK in the presence of detergent (Fig. 6A, lane 8). These
results indicate that the C-terminus of the vOka ORF0 is presented on
the surface of virus particles, but the N-terminus of both vOka and
pOka ORF0 faces the tegument (Fig. 6B).Construction of pOka and vOka recombinant viruses bearing each other's
ORF0
To determine whether the C-terminus of the vOka ORF0 altered the
growth of VZV, a recombinant pOka in which the native ORF0 was
Fig. 7. Growth of ORF0 recombinant viruses and their intracellular protein expression. (A)MeWo cells were infected with rpOka, rpOka-vORF0, rvOka, or rvOka-pORF0 by cell-to-cell
spread. Cell lysates were separated by SDS–PAGE and analyzed by western blotting. (B) MeWo cells infected with rpOka, rpOka-vORF0, rvOka, or rvOka-pORF0 were cultured for
1 week, ﬁxed, and stained with 1% crystal violet.
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bearing the pOkaORF0 (rvOka-pORF0)were constructed by single-base
substitution, as described in the Materials and methods. The successful
substitution of the ORF0 stop codon was veriﬁed by sequencing,
southern blotting (data not shown), and western blotting (Fig. 7A).
There was no difference fromwild-type VZV in the mean plaque size of
either recombinant virus (Fig. 7B) in MeWo cells, indicating that the
mutant C-terminus of the vOka ORF0 does not affect VZV growth.
To generate an ORF0-deﬁcient virus, we constructed a recombi-
nant virus rpOka-ORF0ΔTMD, which lacked the TMD of ORF0. No
ORF0 protein was detected in rpOka-ORF0ΔTMD-infected cell lysates
(Fig. 8A, ORF0). The ORF1 protein, which is a neighboring gene
product of ORF0, was detected in the rpOka-infected cell lysates
(Fig. 8A, ORF1), indicating that the neighboring gene was expressed
normally. Viral gB was used as the marker of infection (Fig. 8A, gB).
The amount of ORF0 RNA was decreased in the rpOka-ORF0ΔTMD-
infected cells compared to the rpOka-infected cells (Fig. 8B). The
growth of the rpOka-ORF0ΔTMD virus was not impaired in the
plaque-formation assay using MeWo cells (Fig. 8C). Because the
amount of ORF0 RNA was decreased in the rpOka-ORF0ΔTMD-
infected cells by RT-PCR (Fig. 8B), the amount of ORF0 cDNA was
compared with ORF1 cDNA by real-time PCR analysis. The copy
number of ORF1 cDNA was set at 100%, and the abundance of ORF0Fig. 8. Growth of ORF0-mutant-expressing virus. (A) MeWo cells were infected with the mut
PAGE and analyzed by western blotting. (B) RT-PCR. Total RNA was puriﬁed from virus-infe
transcriptase, VZV ORF0 and human elongation factor (EF) cDNAs were ampliﬁed by PCR. (C)
were cultured for 2 weeks, ﬁxed, and stained with 1% crystal violet.cDNA compared to ORF1 cDNA in the rpOka-infected cells was 97%,
but it was 18% in the rpOka-ORF0ΔTMD-infected cells.
Discussion
The point mutation at the stop codon of pOka ORF0 caused the
molecular weight differences in the ORF0 protein variant expressed
by vOka. Because of this point mutation, the amino acid sequence at
the C-terminus of vOka ORF0 was increased by 26 amino acids. When
the stop codon was mutated in recombinant viruses, the molecular
weight of the resulting ORF0 protein was changed to that of the vOka
forms. These results indicate that the mutated C-terminal region of
vOka ORF0 is responsible for its difference in molecular weight from
pOka ORF0.
The N-terminus of the ORF0 protein was protected from ProK
treatment, indicating that the N-terminus of the transmembrane
domain faces the inside of the virus particle. Given the mechanisms of
herpesvirus envelopment (Mettenleiter, 2002), the N-terminus of
ORF0 must face the cytoplasm in infected cells and the inside of virus
particles in virions. The C-terminus of vOka ORF0 was presented on
the surface of virus particles, and it appears to be N-glycosylated at its
C-terminus. The pOka and vOka ORF0 have two putative N-
glycosylation sites at amino acid positions 65 to 67 and 126 to 128.ant virus or rpOkaORF0ΔTMD by cell-to-cell spread. Cell lysates were separated by SDS–
cted MeWo cells. After the cDNAs were synthesized with (+) or without (−) reverse
MeWo cells infected with an rpOka ORF0mutant lacking the TMD or rpOkaORF0ΔTMD,
286 T. Koshizuka et al. / Virology 405 (2010) 280–288Although the pOka ORF0 possesses a putative N-glycosylation site at
its C-terminus, it was not glycosylated, indicating that its C-terminus
was inaccessible for glycosylation.
Given that the pOka and vOka ORF0s share their N-terminal and
transmembrane sequences and that the N-terminus of both ORF0
proteins faces the cytoplasm of infected cells and the tegument of
virus particles, the pOka and vOka ORF0s may interact with the same
proteins and have similar N-terminally mediated functions. However,
because of their different C-terminal sequences, their C-terminally
mediated functions probably differ.
Todate, the function of ORF0 remains unknown. TheHSV-2 homolog
of ORF0, UL56, which is mainly located at the perinuclear region of the
cytoplasm (Koshizuka et al., 2002), associates with a ubiquitin E3 ligase,
Nedd4, through the PY motif of UL56 (Ushijima et al., 2008). Because
ORF0 also has a PY motif, it may also associate with Nedd4 family
proteins. However, the intracellular localization of ORF0 differs from
that of HSV-2 UL56, and therefore, ORF0 may possess one or more
unique functions. In our experiments, viruses bearing the ORF0 stop
codon mutants grew just as well as the wild-type virus, suggesting that
the ORF0mutationmay not be related to the attenuation of vOka or that
multiple point mutations of the VZV genome, including those in ORF0,
may be necessary for the attenuation.
Similarly, even the complete removal of the ORF0 protein did not
affect virus growth in our hands. A recombinant virus that lacked the
TMD of ORF0 grew normally in MeWo cells, even though we conﬁrmed
that ORF0 was not expressed in them. This ﬁnding contradicts that of
Zhang and colleagues, who reported that virus lacking the ORF0 gene
showed severely retarded growth in vitro and in vivo (Zhang et al.,
2007). However, in their study, Zhang et al. (2007) deleted the entire
ORF0 sequence, whereas we removed only the TMD. Therefore, the
discrepancy between our reports may be explained if the growth of the
virus was affected by the deletion of the additional sequences rather
than by the loss of ORF0 expression. The nucleotide sequences in the
vicinity of the ORF0 gene may be important for DNA cleavage and/or
packaging of the VZV genome because the ORF0 gene is located at the
genomic terminus. Alternatively, the C-terminal region of ORF0may not
affect the viral growth.
Although weak RNA expression of the TMD-deleted ORF0 was
detected by RT-PCR, the protein was not detectable by western
blotting. The C-terminal TMD-deleted ORF0 protein should be
detectable by the anti-ORF0 serum because this mono-speciﬁc
serumwas raised against the N-terminal region (amino acid positions
1–99) of the ORF0 protein. Therefore, this mutant ORF0 protein may
not be expressed or may be expressed at an undetectable level in the
recombinant virus-infected cells. Alternatively, the truncated ORF0
may be less stable than the wild-type protein, thus resulting in our
inability to detect the protein.
A difference in the cellular localization patterns between the
ORF0s of pOka and vOka might have suggested differing functions for
these proteins. However, the ORF0 proteins of both pOka and vOka
accumulated in the perinuclear region of the cytoplasm in infected
MRC5 andMeWo cells, and both ORF0s partially colocalizedwith gB in
infected MRC5 cells. Both ORF0s were located at the cell rim of
infectedMeWo cells, indicating that they were localized to the plasma
membrane, like the ORF1 protein (Koshizuka et al., 2008). Thus, the
localization patterns of the pOka and vOka ORF0 proteins did not
differ substantially, and no clues to functional differences could be
obtained from these data.
However, one way the function of the vOka ORF0 might be altered
is through the N-linked glycosylation of its C-terminus, which we
discovered because the bands of vOka ORF0 were smeared on
immunoblots of infected and transfected cells. This novel modiﬁcation
might, in particular, affect vOka cell tropism. In the case of measles
virus, the vaccine strain uses both SLAM and CD46 as receptors,
whereas most wild-type strains use only SLAM (Dorig et al., 1993;
Erlenhofer et al., 2002; Tatsuo et al., 2000). Point mutations in thehemagglutinin protein of the vaccine strain account for the measles
virus's use of CD46 (Tahara et al., 2007). The C-terminus of vOka ORF0
may affect the attachment of vOka virus particles to target cells, by
altering its interactions with cellular molecules. If this scenario is
correct, antibodies raised against the C-terminus of vOka ORF0may be
responsible for the neutralization of the virus. In addition, some other
post-translational modiﬁcation(s) may contribute to changes in vOka
ORF0 function. Even after the N-glycosylation was removed by
digestion with PNGase-F, the band pattern of vOka ORF0 was still
smeared. This issue will be addressed in future studies.
Materials and methods
Cells and viruses
MRC-5 cells were cultured in minimum essential medium (MEM)
supplemented with 10% fetal bovine serum (FBS). Human melanoma
cells (MeWo) and 293T cells were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% FBS. The VZV
strains, pOka and vOka, were propagated in MRC-5 cells or MeWo
cells. The preparation of cell-free viruses and the puriﬁcation of virus
particles from the infected MeWo cells were described previously
(Koshizuka et al., 2008). Puriﬁed virus particles were analyzed by
electron microscopy with negative staining, as described previously
(Sadaoka et al., 2007).
Plasmids
The Escherichia coli expression plasmid pGEX-ORF0 was con-
structed by amplifying the domains encoding ORF0 codons 1 to 99 by
PCR from the pOka genome and cloning the resulting DNA fragment
into pGEX-4T-1 (GE Healthcare Biosciences, Piscataway, NJ) in frame
with glutathione-S-transferase (GST). In pGEX-ORF0, the initiation
methionine of ORF0 was altered to alanine. Total RNAs were extracted
from pOka- or vOka-infected MeWo cells by TRIzol reagent (Invitro-
gen, Carlsbad, CA), according to themanufacturer's manual. The cDNA
was prepared by reverse transcription (RT) with oligo(dT) using the
Superscript III kit (Invitrogen). The DNA fragment of full-length ORF0
was ampliﬁed from pOka cDNA by PCR with primers ORF0-f1
(GGGGGCGGCCGCCATGGCGACCGTGCACTAC; NotI site is underlined)
and ORF0-r3 (GGGGCTCGAGTCATGTAGTTGAGTTGGG; XhoI site is
underlined). The DNA fragment was cloned into pCAGGS-MCS (Niwa
et al., 1991) to generate pCAGGS-pORF0.
The vOka ORF0 was ampliﬁed from vOka cDNA by PCR with
primers ORF0-f1 and ORF0-r4 (GGGGCTCGAGTCAGCATACAGAGCT-
TATGCAG; XhoI site is underlined), cloned into pCR2.1-TOPO
(Invitrogen), and sequenced. Spliced vOka ORF0 cDNA was ampliﬁed
by PCR with ORF0-f1 and ORF0-rvA (GGGCTCGAGTTATTCCACTGGTT-
GATGTCC; XhoI site is underlined) and cloned into pCAGGS-MCS to
generate pCAGGS-vORF0A. The splicing donor site of unspliced
vOka ORF0 was substituted by PCR with primers splice-mutF
(CCGGAAGGGGAAGGCATTTATTCTCGCTTG) and splice-mutR
(CAAGCGAGAATAAATGCCTTCCCCTTCCGG) to generate a splicing-
incompetent mutant, pCAGGS-vORF0N.
Antibodies
The GST-ORF0 (amino acid positions 1–99) fusion protein was
puriﬁed with glutathione sepharose beads (GE Healthcare Bioscience)
and used as an antigen to generate rabbit anti-ORF0 mono-speciﬁc
antibodies. The puriﬁcation of anti-ORF0 was performed as described
previously (Koshizuka et al., 2008). The anti-glycoprotein B (gB), anti-
ORF16, and anti-ORF49 rabbit antibodies were described previously
(Sadaoka et al., 2007). The anti-gB monoclonal antibody was
described previously (Okuno et al., 1983). The anti-EEA1 (clone 14;
BD Biosciences Pharmingen) monoclonal antibody was purchased.
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MRC-5 orMeWo cells were grown on coverslips and subjected to an
immunoﬂuorescence assay as described previously (Koshizuka et al.,
2008).
Transfection
MeWo cells were transfected with the indicated plasmids by
Lipofectamine2000 reagent (Invitrogen)accordingto themanufacturer's
instructions. 293T cells were transfected with the indicated plasmids by
the calcium phosphate method. Ten micrograms of plasmid DNA was
combined with 50 μl of 2.5 M CaCl2 and 440 μl of sterile water. The
calcium–DNA solution was mixed with 2× HEPES-buffered saline
(140 mM NaCl, 1.5 mM Na2HPO4, 50 mM HEPES, pH 7.1). After
incubation at RT for 30 min, the calcium phosphate–DNA suspension
was transferred to the 293T cells. After another incubation, the medium
was changed, and the293T cellswere harvested at 72 hpost transfection.
Puriﬁcation of virus particles
VZV virions were puriﬁed as described previously (Sadaoka et al.,
2007). After the second Histodenz gradient puriﬁcation, the virus
particle-containing fraction was diluted with PBS and pelleted by
centrifugation at 27,000 rpm for 2 h at 4 °Cwith a P40ST rotor (Hitachi).
The pellet was suspended in PBS and layered onto a continuous 10–40%
CsCl gradient, followed by centrifugation at 20,000 rpm for 48 h at 4 °C
with a P40ST rotor (Hitachi). Fractions were collected from the bottom
and analyzed bywestern blotting. Viral DNAwas puriﬁed from fractions
and analyzed by PCR using the primer pair ORF0-f1 and ORF0-r2
(GTCGACCTCACGGTACACAGCATTTGCG).
Protease assay
The protease assays were performed essentially as described
previously (Koshizuka et al., 2002). Protease inhibitor cocktail
(Sigma) was added to puriﬁed virus particles to prevent unexpected
proteolysis. The puriﬁed virus particles were treated with ProK at a
ﬁnal concentration of 500 μg/ml in the presence or absence of 1%
Triton X-100. After an incubation at 37 °C for 30 min, 2 mM PMSF was
added to the samples to terminate the ProK reaction, and the samples
were incubated on ice for 5 min. The samples were subjected to SDS–
PAGE without boiling and analyzed by western blotting.
BAC mutagenesis
The recombinant pOka virus (rpOka) was constructed as previ-
ously reported (Nagaike et al., 2004; Yoshii et al., 2007). In brief,
rpOka was reconstituted by transfecting MRC-5 cells with the pOka-
BAC genome (pOka-BAC) (Nagaike et al., 2004; Yoshii et al., 2007). To
remove the BAC sequence, the MRC-5 cells were ﬁrst infected with a
recombinant adenovirus, AxCANCre, which expresses the Cre recom-
binase (kindly provided by Dr. Y. Kawaguchi). The cells were then
super-infected with the recombinant virus and cultured until plaques
without GFP appeared (Kanegae et al., 1995; Tanaka et al., 2003).
To generate recombinant virus with the C-terminus TMD of ORF0
deleted (rpOkaORF0ΔTMD), nucleotide positions 457–589 of the
pOka genome were replaced with a kanamycin resistance (Kmr) gene.
The DNA fragments containing the Kmr gene were ampliﬁed with
primers dORF0TMDfw407-456 (5′-ATGATGGAATCCACAGACTT-
CAGCTGGCTTTTCTAAGAATTCGCAAATGCGAAGTTCCTATTCTCTA-
GAAAGTATAGGAACTTCAGCAAGCGAACCGGAATTGC-3 ′) and
dORF0TMDrv590-541 (5′-TAAATACCTTCCCCTTCCGGACAGTAGTTT-
CATGTAGTTGAGTTGGGAGGGAAGTTCCTATACTTTCTAGAGAATAG-
GAACTTCCTTTTTCAATTCAGAAGAACTC-3′). The DNA fragments were
introduced by electroporation into E. coli DH10B harboring the pOka-BAC genome and pGETrec, whichwas a kind gift fromDr. P. A. Ioannou
(Narayanan et al., 1999).
To generate recombinant viruses in which the ORF0 of vOka was
replaced by the one for pOka and vice-versa, the stop codon of pOka
ORF0 (at nucleotide position 560 of theVZV genome)was replacedwith
the codon for arginine, and the arginine codon of vOka ORF0 was
replaced with the stop codon. These changes were performed using a
two-step Red-mediated mutagenesis procedure (Tischer et al., 2006) in
E. coli GS1783, essentially as described by Jarosinski et al. (2007). E. coli
GS1783 harboring the pOka-BAC or vOka-BAC genome was used. The
primer pairs for the ampliﬁcation were as follows: ORF0pv1 (5′-
GTTGCCGTTTTTCCCGAGGAACCTCCCAACTCAACTACACGAAAC-
TACTGTCCGGAAGGGAGGATGACGACGATAAGTAGGG-3′) and ORF0pv2
(5′-AAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCGTGTAGTT-
GAGTTGGGAGGTCAACCAATTAACCAATTCTGATTAG-3′) or ORF0vp1
(5′-GTTGCCGTTTTTCCCGAGGAACCTCCCAACTCAACTACATGAAAC-
TACTGTCCGGAAGGGAGGATGACGACGATAAGTAGGG-3′) and ORF0vp2
(5′-AAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCATGTAGTT-
GAGTTGGGAGGTCAACCAATTAACCAATTCTGATTAG-3′). The substitu-
tion site is underlined. The successful recombination was conﬁrmed
by PCR and southern blotting. MeWo cells were transfected with the
recombinant virus genomes by using the Lipofectamine 2000 reagent.
Growth analysis of recombinant viruses
MeWo cells were infected with cell-free rpOka, rpOka-vORF0,
rvOka, rvOka-pORF0, or rpOkaORF0ΔTMD viruses and incubated at
37 °C. The medium was replaced every 2 days, and the cells were
stained with 1% crystal violet/70% ethanol for analysis (Yoshii et al.,
2008).
RT-PCR and real-time PCR
Total RNA was isolated from the recombinant virus-infected MeWo
cells using TRIzol (Invitrogen), and its concentration and purity were
determined by spectrophotometry. The RNA integrity was veriﬁed by
electrophoresis on 1.2% denaturing formaldehyde gels. Onemicrogram of
total RNA was transcribed using Superscript III reverse transcriptase
(Invitrogen). An equal amount of cDNA (1/10of the reaction)was used in
each PCR. PCRwas performed using GoTaq GreenMasterMix (Promega).
A primer pair for the human elongation factor gene was used as the
control (EF-F: GCTCCAGCATGTTGTCACCATTC; EF-R: GGTGAATTT-
GAAGCTGGTATCTC). The ORF0 cDNA was detected using primers ORF0-
f1 and ORF0-reverse (GTGCCATTCTCCACGTGAGG).
SYBR Green PCRs were performed in an Applied Biosystems 7300
real-time PCR system (Applied Biosystems, Foster City, CA) with
speciﬁc primers for ORF0 (ORF0-f1 and ORF0-reverse:GTGCCATTCTC-
CACGTGAGG) and ORF1 (ORF1-1f: GAATTCGCGTCCAGGGTATCG-
GAGTA and ORF1-2r: CTCGAGTTAGCATAACCTGTCCATTTGCAT),
according to the manufacturer's manual. The thermal proﬁle for all
SYBR Green PCRs was 95 °C for 10 min, followed by 40 cycles of 95 °C
for 10 s, 58 °C for 20 s, and 72 °C for 30 s. At the end of each SYBR
Green PCR run, data analysis was performed by the SDS program
version 1.4 (Sequence Detection Software; Applied Biosystems). Each
sample was analyzed in duplicate.
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